FDA Releases Draft Guidance on Evaluating Prescription Use Drugs of Abuse Assays

Summary

The Food and Drug Administration (FDA) has made available a draft guidance document outlining the principles it uses to evaluate premarket notifications for prescription use drugs of abuse assays, specifically for in vitro diagnostic submissions seeking 510(k) clearance.